Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
{{output}}
Background: In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction-associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue, reduced fibrosi... ...
